Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9H6X2

UPID:
ANTR1_HUMAN

ALTERNATIVE NAMES:
Tumor endothelial marker 8

ALTERNATIVE UPACC:
Q9H6X2; A8K7U8; J7K7G4; J7KF88; Q4ZFV6; Q53QD8; Q96P02; Q9NVP3

BACKGROUND:
The Anthrax toxin receptor 1, known alternatively as Tumor endothelial marker 8, is integral to cell migration and angiogenesis. It facilitates the interaction between cells and the extracellular matrix, playing a pivotal role in endothelial cell responses to angiogenic signals and acting as a receptor for anthrax toxin.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Anthrax toxin receptor 1 could open doors to potential therapeutic strategies for diseases like Hemangioma, capillary infantile, and GAPO syndrome. Its critical functions in cell adhesion and immune response make it a promising target for drug discovery efforts aimed at treating these genetic conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.